ClinicalTrials.gg
RecruitingNCT07715656(COAST)Updated Jul 20, 2026

Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas

An interventional study of embolization therapy Bilateral and embolization therapy Unilateral in Chronic Subdural Hematoma, sponsored by Lahey Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Lahey Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2025, registered May 2026).
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.

Planned enrollment
2nd of 15
400 · median 40
Started
2025
with 3 others
No phase
10 of 22
4 open now
Registered
20th of 22
by date
Lead sponsor
1 of 22
Lahey Clinic

Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 20th registered.

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hematoma, Subdural, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is a pragmatic, prospective, multicenter, randomized controlled trial with intention to treat analysis. In which subjects will receive either unilateral or bilateral middle meningeal artery (MMA) embolization using coils for the treatment of unilateral chronic subdural hematomas (cSDH).

Read the detailed description

This study will enroll up to 400 subjects who will be randomized to receive either unilateral or bilateral coil MMA embolization. The study will assess the effect of the procedures on hematoma size and patient functional outcomes over 1 to 3 months of follow-up.

03

Conditions studied

  • Chronic Subdural Hematoma

Keywords

  • cSDH
  • Chronic subdural hematoma
  • Coils
  • Embolization
  • eMMA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Candidates for this study must meet ALL of the following criteria:

  1. Subject is 18 years of age or older.
  2. Subject has a diagnosis of chronic subdural hematoma with mass effect Determined by brain imaging (CT or MRI) and correlated clinical symptoms.
  3. Pre-randomization modified Rankin Score (mRS) ≤3

    a. Surgical Cohort: Assessment should reflect the subject's condition just prior to undergoing surgery. Assessment may be performed post-surgery using pre-surgical data.

  4. Subdural Hematoma Size

    Medical Management Cohort:

    • Midline shift \< 10mm and hematoma thickness > 10 mm as measured on coronal imaging perpendicular to the skull.
    • No focal deficit related to the chronic subdural hematoma requiring surgical intervention

    Surgical Cohort:

    • No requirement
  5. A CT performed prior to randomization demonstrating stability of the hematoma. Stability is defined as no worsening of midline shift or increase in the size of the cSDH from the screening image that results in new or worsening clinical symptoms.
  6. Patient or designated Legal Authorized Representative, confirms the patient has the mental capacity, willingness and ability to comply with protocol and follow-up requirements
  7. In the opinion of the treating physician, MMA embolization is technically feasible, including evaluation of preoperative CTA, if available, or presence of a foramen spinosum bilaterally.

Exclusion criteria

Exclusion Criteria:

  • Candidates will be excluded from participation if ANY of the following apply:

    1. Patients presenting with an acute SDH (e.g. patient with presenting with a SDH due to trauma); mixed density is permitted.
    2. Subject presents with bilateral cSDHs requiring treatment (contralateral cSDH \<5mm and not requiring treatment is permitted.
    3. Subject presents with Glasgow Coma Scale \< 9
    4. Markwalder assessment >4
    5. cSDH that developed with underlying conditions such as vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, end stage renal disease (ESRD) on hemodialysis, end stage liver disease or other comorbidities causing a coagulopathy
    6. Prior carotid stent placement that crosses the origin of the External Carotid Artery (ECA) ipsilateral to the subdural hematoma
    7. Presumed septic embolus, or suspicion of microbial superinfection
    8. CT or MRI evidence of intra-cranial tumor or mass lesion
    9. Significant to angiography (eg. kidney failure).
    10. of less than 1-year
    11. Women who are pregnant, lactating, plan on becoming pregnant during the course of the clinical investigation. We routinely do pregnancy tests prior to this procedure, to avoid radiation exposure to the fetus including radiation on follow up CT scans
    12. Current involvement in an (drug, device, etc.) clinical trial that may confound study endpoints. Subjects in observational, natural history, and/or epidemiological studies not involving intervention are eligible
    13. Patient unwilling to follow SOC recommendations (e.g. refuses surgery or lifestyle modifications)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Medical Management

    In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils as part of their medical management for chronic subdural hematoma (cSDH). In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.

    Device: embolization therapy Bilateral · Device: embolization therapy Unilateral

  • Active comparator
    Surgical

    In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils in addition to standard surgical management for chronic subdural hematoma (cSDH). In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.

    Device: embolization therapy Bilateral · Device: embolization therapy Unilateral

Interventions

  • Deviceembolization therapy Bilateral

    In the bilateral approach, both middle meningeal arteries are accessed and embolized using coils, regardless of hematoma location. Imaging guidance is used throughout the procedure to ensure proper coil placement, and post-procedure imaging confirms that both vessels are fully occluded.

  • Deviceembolization therapy Unilateral

    In the unilateral approach, the middle meningeal artery (MMA) on the side of the hematoma is accessed via a catheter and occluded using coils under imaging guidance. The procedure targets only the affected side, and follow-up imaging is used to confirm successful embolization and vessel occlusion.

06

What researchers measure

Primary outcomes

  1. Change in cSDH Maximum thickness From Baseline on Non-contrast Head CT

    Change in maximum hematoma thickness (mm) and Volume (mL) measured on non-contrast head CT compared with baseline. Measurements will be performed using standardized imaging review.

    Time frame: Baseline, 1 month (3-6 weeks), and 3 months (10-14 weeks)

Secondary outcomes

  1. Number of Participants Requiring Additional surgical Intervention

    Number of participants requiring additional surgical treatment after randomization, including initial surgical evacuation in the medical management cohort or repeat hematoma evacuation in the surgical cohort.

    Time frame: Through 3 months

  2. Change from Baseline in Modified Rankin scale (mRS) Score

    Functional outcome measured using the Modified Rankin Scale (range 0-6). change from baseline will be reported.

    Time frame: Baseline, 1 month, and 3 months

  3. Number of participants with Procedure-related Serious Adverse Events

    Number of participants experiencing procedure related adverse events, including but not limited to ischemic stroke, intracranial hemorrhage, arterial dissection, vessel perforation, access-site complications requiring intervention, or death.

    Time frame: through 3 months after embolization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 44 interventional studies with no phase under Hematoma, Subdural, Chronic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jul 20, 2026
StartActual
Apr 9, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07715656
Lead sponsor
Lahey Clinic
Responsible party
Jonathan Pace (Medical Doctor, Lahey Clinic) — Principal investigator
First posted
Jul 20, 2026
Start date
Apr 9, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 20, 2026

Study contacts

Sandy L Alvarez, MD
Contact
sandy.l.alvarez@lahey.org
7865800186
Jonathan Pace, MD
principal investigator · Lahey Hospital & Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion